Paper Details

  1. Home
  2. Paper Details

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Author: AllmerCristine, AnsellStephen M, AsmannYan W, BallasZuhair K, ColganJoseph P, GuptaMamta, HabermannThomas M, InwardsDavid J, JohnstonPatrick B, LinkBrian K, MaurerMatthew J, MicallefIvana N M, NowakowskiGrzegorz S, PorrataLuis F, ShanafeltTait D, SmithBrian J, WeinerGeorge J, WisemanGregory A, WitzigThomas E, ZentClive S

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This Phase I trial studied the safety and efficacy of combining CpG 7909 with standard radioimmunotherapy (RIT) for relapsed indolent non-Hodgkin lymphoma. The combination was well-tolerated, with an overall response rate of 93% and a complete remission rate of 63%. Median progression-free survival was 42.7 months and median duration of response was 35 months.
Paper Details　
Original Abstract of the Article :
Radioimmunotherapy (RIT) for relapsed indolent non-Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B-cells, are immunostimulatory, and can produce responses when injected intratumorally and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23619698

データ提供：米国国立医学図書館（NLM）

A Powerful Combination for Relapsed B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (NHL) is a type of cancer affecting the lymphatic system. Radioimmunotherapy (RIT) is a promising treatment, but sometimes the cancer returns. This study investigated a combination therapy using both RIT and an immunostimulatory compound called CpG 7909, aiming to improve treatment outcomes for relapsed NHL.

High Response Rates and Long Duration of Response

The results were impressive. The combined treatment achieved a high overall response rate of 93%, with 63% of patients achieving complete remission. The median progression-free survival was 42.7 months, and the median duration of response was 35 months. These findings suggest that the combination therapy could offer significant benefits for patients with relapsed B-cell NHL.

Boosting the Immune System for a Stronger Fight

The research also showed that CpG 7909 modulated the immune system, potentially contributing to the improved response. These results warrant further investigation to confirm the safety and efficacy of this combination therapy for relapsed NHL patients. It highlights the potential of harnessing the power of the immune system to fight cancer effectively.

Dr.Camel's Conclusion

In the battle against cancer, we must be innovative. This study demonstrates the potential of a combination therapy to achieve impressive results in patients with relapsed B-cell NHL. It reminds us that the desert of cancer research is vast, but by combining knowledge and creativity, we can find new ways to conquer this formidable disease.
Date :
  1. Date Completed 2014-03-27
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23619698

DOI: Digital Object Identifier

NIHMS503041

Related Literature

Article Analysis
・Effects of ibritumomab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.